Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study

Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.


Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min and Day 1 in ketamine responders versus non-responders in 31 depressed subjects and 25 healthy controls. A significant difference in peak gamma power was seen in the depressed ketamine responders versus non-responders. These results implicate AMPA throughput in ketamine's mechanism of antidepressant action.

Trial registration: NCT00088699.

Keywords: Depression; Ketamine; Magnetoencephalography (MEG).

Publication types

  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anesthetics, Dissociative / pharmacology
  • Anesthetics, Dissociative / therapeutic use
  • Antidepressive Agents / pharmacology
  • Antidepressive Agents / therapeutic use
  • Cross-Over Studies
  • Depressive Disorder, Major / diagnostic imaging
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Treatment-Resistant / diagnostic imaging
  • Depressive Disorder, Treatment-Resistant / drug therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Ketamine / pharmacology
  • Ketamine / therapeutic use*
  • Magnetoencephalography / drug effects*
  • Magnetoencephalography / methods
  • Male
  • Synaptic Potentials / drug effects*
  • Synaptic Potentials / physiology
  • Time Factors
  • Treatment Outcome


  • Anesthetics, Dissociative
  • Antidepressive Agents
  • Ketamine

Associated data